Mr. Ngan has over 20 years of experience in life sciences, with a wealth of fundraising and global business development success across biotech startups and venture-backed companies, through to large publicly traded biotechnology and pharmaceutical companies.   Mr. Ngan has directly led or facilitated over $1 billion in financing and partnership transactions.
Mr. Ngan previously held business development and corporate finance roles at SinoVeda, Cytochroma (now Opko Health), and Shire plc (now Takeda) in positions of increasing responsibility.  His depth of experience includes equity research roles at National Bank Financial and Canaccord Adams, where he evaluated innovative products and technologies in the therapeutics and medical device industries.  He started his career working in investor relations with the infectious disease specialist, BioChem Pharma.

Mr. Ngan holds an M.B.A. (Finance) from Queen’s University and an undergraduate degree in Immunology from the University of Toronto.  He is also a CFA charterholder.

• 

  Vice President, Business Development in Kisoji

  Breakthrough antibody discovery for breakthrough therapeutics